Published in Circ Cardiovasc Genet on December 01, 2008
Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on. Biochem Pharmacol (2010) 1.14
Human PON1, a biomarker of risk of disease and exposure. Chem Biol Interact (2010) 1.09
Paraoxonase 1 (PON1) modulates the toxicity of mixed organophosphorus compounds. Toxicol Appl Pharmacol (2009) 1.06
Repeated developmental exposure of mice to chlorpyrifos oxon is associated with paraoxonase 1 (PON1)-modulated effects on cerebellar gene expression. Toxicol Sci (2011) 1.02
Paraoxonase 1 status as a risk factor for disease or exposure. Adv Exp Med Biol (2010) 0.99
Paraoxonase 1 (PON1) as a genetic determinant of susceptibility to organophosphate toxicity. Toxicology (2012) 0.99
Household organophosphorus pesticide use and Parkinson's disease. Int J Epidemiol (2013) 0.98
Paraoxonase 1 (PON1) polymorphisms, haplotypes and activity in predicting cad risk in North-West Indian Punjabis. PLoS One (2011) 0.95
Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease. Pharmacogenomics (2013) 0.91
Dietary cholesterol increases paraoxonase 1 enzyme activity. J Lipid Res (2012) 0.88
HDL-3 is a superior predictor of carotid artery disease in a case-control cohort of 1725 participants. J Am Heart Assoc (2014) 0.87
Additional Common Polymorphisms in the PON Gene Cluster Predict PON1 Activity but Not Vascular Disease. J Lipids (2012) 0.87
Human paraoxonase-1 (PON1): Gene structure and expression, promiscuous activities and multiple physiological roles. Gene (2015) 0.83
Novel common and rare genetic determinants of paraoxonase activity: FTO, SERPINA12, and ITGAL. J Lipid Res (2012) 0.83
Relationship of human paraoxonase-1 serum activity and genotype with atherosclerosis in individuals from the Deep South. Pharmacogenet Genomics (2011) 0.83
The toxicity of mixtures of specific organophosphate compounds is modulated by paraoxonase 1 status. Adv Exp Med Biol (2010) 0.80
Paraoxonase and coronary heart disease risk: language misleads, linkage misinforms, function clarifies. Circ Cardiovasc Genet (2008) 0.80
Dietary fatty acid intake is associated with paraoxonase 1 activity in a cohort-based analysis of 1,548 subjects. Lipids Health Dis (2013) 0.79
The determination of Q192R polymorphism of paraoxonase 1 by using non-toxic substrate p-nitrophenylacetate. Indian J Hum Genet (2013) 0.78
Paraoxonases-1, -2 and -3: What are their functions? Chem Biol Interact (2016) 0.76
Paraoxonase-1 and Early-Life Environmental Exposures. Ann Glob Health (2016) 0.75
Combined Effects of Curcumin and Lycopene or Bixin in Yoghurt on Inhibition of LDL Oxidation and Increases in HDL and Paraoxonase Levels in Streptozotocin-Diabetic Rats. Int J Mol Sci (2017) 0.75
The common variant Q192R at the paraoxonase 1 (PON1) gene and its activity are responsible for a portion of the altered antioxidant status in type 2 diabetes. Exp Biol Med (Maywood) (2016) 0.75
Low paraoxonase 1 arylesterase activity and high von Willebrand factor levels are associated with severe coronary atherosclerosis in patients with non-diabetic stable coronary artery disease. Med Sci Monit (2014) 0.75
A COMPARISON OF ESTIMATES OF MICHAELIS-MENTEN KINETIC CONSTANTS FROM VARIOUS LINEAR TRANSFORMATIONS. J Biol Chem (1965) 11.92
Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature (1998) 3.84
Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest (1998) 3.34
Serum esterases. II. An enzyme hydrolysing diethyl p-nitrophenyl phosphate (E600) and its identity with the A-esterase of mammalian sera. Biochem J (1953) 3.33
Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett (1991) 3.10
The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet (1993) 2.88
The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet (1996) 2.57
Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet (2004) 2.55
The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics (1996) 2.48
Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet (1995) 2.29
Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet (1993) 2.12
Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease. Arterioscler Thromb Vasc Biol (2003) 2.01
Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler Thromb Vasc Biol (2000) 1.94
Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics (1999) 1.88
Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet (2001) 1.85
Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. Pharmacogenetics (2000) 1.79
Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler Thromb Vasc Biol (2001) 1.79
Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol (2001) 1.76
PON1 status of farmworker mothers and children as a predictor of organophosphate sensitivity. Pharmacogenet Genomics (2006) 1.75
Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J Biol Chem (2000) 1.62
Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur J Biochem (1993) 1.57
Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin Sci (Lond) (2004) 1.56
Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol (2000) 1.53
Pharmacogenetics of paraoxonases: a brief review. Naunyn Schmiedebergs Arch Pharmacol (2003) 1.50
Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence. Biochemistry (1991) 1.46
Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics (2001) 1.46
Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest (1997) 1.45
Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol (1999) 1.42
Expression of human paraoxonase (PON1) during development. Pharmacogenetics (2003) 1.40
Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem (1986) 1.37
Paraoxonase-1 promoter haplotypes and serum paraoxonase: a predominant role for polymorphic position - 107, implicating the Sp1 transcription factor. Biochem J (2003) 1.30
Toxicity of chlorpyrifos and chlorpyrifos oxon in a transgenic mouse model of the human paraoxonase (PON1) Q192R polymorphism. Pharmacogenet Genomics (2005) 1.30
Paraoxonase protects against chlorpyrifos toxicity in mice. Toxicol Lett (1995) 1.22
Paraoxonase 1 and atherosclerosis: is the gene or the protein more important? Free Radic Biol Med (2004) 1.19
Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase. Proc Natl Acad Sci U S A (1995) 1.17
Paraoxon hydrolysis in human serum mediated by a genetically variable arylesterase and albumin. Am J Hum Genet (1984) 1.17
A long and winding road: defining the biological role and clinical importance of paraoxonases. Clin Chem Lab Med (2006) 1.14
Novel paraoxonase (PON1) nonsense and missense mutations predicted by functional genomic assay of PON1 status. Pharmacogenetics (2003) 1.14
Two alleles of the human paraoxonase gene produce different amounts of mRNA. An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. Arterioscler Thromb Vasc Biol (1997) 1.12
Decreased stability of the M54 isoform of paraoxonase as a contributory factor to variations in human serum paraoxonase concentrations. J Lipid Res (2001) 1.12
Serum paraoxonase status: a major factor in determining resistance to organophosphates. J Toxicol Environ Health (1993) 1.10
A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression. Atherosclerosis (2000) 1.09
Determination of paraoxonase 1 status and genotypes at specific polymorphic sites. Curr Protoc Toxicol (2004) 0.99
Genetic and environmental determinants of the PON-1 phenotype. Eur J Clin Invest (2007) 0.98
The association of the PON1 Q192R polymorphism with complications and outcomes of pregnancy: findings from the British Women's Heart and Health cohort study. Paediatr Perinat Epidemiol (2006) 0.94
The separation of sheep and human serum "A"-esterase activity into the lipoprotein fraction by ultracentrifugation. Comp Biochem Physiol B (1985) 0.94
Serum paraoxonase (PON1) isozymes: the quantitative analysis of isozymes affecting individual sensitivity to environmental chemicals. Drug Metab Dispos (2001) 0.81
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
The eMERGE Network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies. BMC Med Genomics (2011) 9.20
Ethical and practical guidelines for reporting genetic research results to study participants: updated guidelines from a National Heart, Lung, and Blood Institute working group. Circ Cardiovasc Genet (2010) 6.74
Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med (2014) 5.47
Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. Nat Biotechnol (2013) 4.85
Reporting genetic results in research studies: summary and recommendations of an NHLBI working group. Am J Med Genet A (2006) 4.56
The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future. Genet Med (2013) 4.37
Use of diverse electronic medical record systems to identify genetic risk for type 2 diabetes within a genome-wide association study. J Am Med Inform Assoc (2011) 4.20
Actionable, pathogenic incidental findings in 1,000 participants' exomes. Am J Hum Genet (2013) 4.06
Variants near FOXE1 are associated with hypothyroidism and other thyroid conditions: using electronic medical records for genome- and phenome-wide studies. Am J Hum Genet (2011) 3.85
Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet (2012) 3.68
Association of in utero organophosphate pesticide exposure and fetal growth and length of gestation in an agricultural population. Environ Health Perspect (2004) 3.66
Genomic research and wide data sharing: views of prospective participants. Genet Med (2010) 3.45
Return of individual research results from genome-wide association studies: experience of the Electronic Medical Records and Genomics (eMERGE) Network. Genet Med (2012) 3.29
Glad you asked: participants' opinions of re-consent for dbGap data submission. J Empir Res Hum Res Ethics (2010) 3.29
Recommendations for returning genomic incidental findings? We need to talk! Genet Med (2013) 3.23
Toll-like receptor 1 polymorphisms affect innate immune responses and outcomes in sepsis. Am J Respir Crit Care Med (2008) 2.64
National Institutes of Health State-of-the-Science Conference Statement: Family History and Improving Health. Ann Intern Med (2009) 2.58
Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. Am J Hum Genet (2012) 2.53
Association between in utero organophosphate pesticide exposure and abnormal reflexes in neonates. Neurotoxicology (2005) 2.49
Presence of intraplaque hemorrhage stimulates progression of carotid atherosclerotic plaques: a high-resolution magnetic resonance imaging study. Circulation (2005) 2.36
Apolipoprotein E genotype and neurodevelopmental sequelae of infant cardiac surgery. J Thorac Cardiovasc Surg (2003) 2.25
Periventricular leukomalacia is common after neonatal cardiac surgery. J Thorac Cardiovasc Surg (2004) 2.19
Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height. Am J Hum Genet (2010) 2.15
The FDA and genomic tests--getting regulation right. N Engl J Med (2015) 2.09
Processes and preliminary outputs for identification of actionable genes as incidental findings in genomic sequence data in the Clinical Sequencing Exploratory Research Consortium. Genet Med (2013) 2.08
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
Genome- and phenome-wide analyses of cardiac conduction identifies markers of arrhythmia risk. Circulation (2013) 2.06
Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease. Arterioscler Thromb Vasc Biol (2003) 2.01
Genetic variants associated with the white blood cell count in 13,923 subjects in the eMERGE Network. Hum Genet (2011) 2.00
ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing. J Mol Diagn (2012) 1.99
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. Am J Hum Genet (2012) 1.96
A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. Am J Hum Genet (2005) 1.96
Technical desiderata for the integration of genomic data into Electronic Health Records. J Biomed Inform (2011) 1.96
Vitamin C and E intake is associated with increased paraoxonase activity. Arterioscler Thromb Vasc Biol (2002) 1.93
Perioperative stroke in infants undergoing open heart operations for congenital heart disease. Ann Thorac Surg (2009) 1.82
Modulation of paraoxonase (PON1) activity. Biochem Pharmacol (2005) 1.80
Arterial remodeling in [corrected] subclinical carotid artery disease. JACC Cardiovasc Imaging (2009) 1.74
Patient characteristics are important determinants of neurodevelopmental outcome at one year of age after neonatal and infant cardiac surgery. J Thorac Cardiovasc Surg (2007) 1.71
Complement receptor 1 gene variants are associated with erythrocyte sedimentation rate. Am J Hum Genet (2011) 1.66
The relationship of postoperative electrographic seizures to neurodevelopmental outcome at 1 year of age after neonatal and infant cardiac surgery. J Thorac Cardiovasc Surg (2005) 1.65
Neurodevelopmental outcomes after staged palliation for hypoplastic left heart syndrome. Pediatrics (2008) 1.55
Functional genomic of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu Rev Med (2001) 1.51
Postoperative electroencephalographic seizures are associated with deficits in executive function and social behaviors at 4 years of age following cardiac surgery in infancy. J Thorac Cardiovasc Surg (2013) 1.50
Informed Consent in Genome-Scale Research: What Do Prospective Participants Think? AJOB Prim Res (2012) 1.50
Predictors of carotid atherosclerotic plaque progression as measured by noninvasive magnetic resonance imaging. Atherosclerosis (2006) 1.48
A genome- and phenome-wide association study to identify genetic variants influencing platelet count and volume and their pleiotropic effects. Hum Genet (2013) 1.47
Increasing duration of deep hypothermic circulatory arrest is associated with an increased incidence of postoperative electroencephalographic seizures. J Thorac Cardiovasc Surg (2005) 1.45
Measurement of paraoxonase (PON1) status as a potential biomarker of susceptibility to organophosphate toxicity. Clin Chim Acta (2005) 1.42
Leveraging the electronic health record to implement genomic medicine. Genet Med (2012) 1.42
Expression of human paraoxonase (PON1) during development. Pharmacogenetics (2003) 1.40
Genome-wide association study of plasma lipoprotein(a) levels identifies multiple genes on chromosome 6q. J Lipid Res (2009) 1.34
Follow-up of carriers of BRCA1 and BRCA2 variants of unknown significance: variant reclassification and surgical decisions. Genet Med (2011) 1.32
Polymorphisms of the IL1-receptor antagonist gene (IL1RN) are associated with multiple markers of systemic inflammation. Arterioscler Thromb Vasc Biol (2008) 1.32
Apolipoprotein E genotype modifies the risk of behavior problems after infant cardiac surgery. Pediatrics (2009) 1.30
Toxicity of chlorpyrifos and chlorpyrifos oxon in a transgenic mouse model of the human paraoxonase (PON1) Q192R polymorphism. Pharmacogenet Genomics (2005) 1.30
Loci influencing blood pressure identified using a cardiovascular gene-centric array. Hum Mol Genet (2013) 1.27
WNT1 mutations in families affected by moderately severe and progressive recessive osteogenesis imperfecta. Am J Hum Genet (2013) 1.27
Pitfalls of merging GWAS data: lessons learned in the eMERGE network and quality control procedures to maintain high data quality. Genet Epidemiol (2011) 1.26
Paraoxonase (PON 1) as a biomarker of susceptibility for organophosphate toxicity. Biomarkers (2003) 1.25
Is cardiac diagnosis a predictor of neurodevelopmental outcome after cardiac surgery in infancy? J Thorac Cardiovasc Surg (2010) 1.24
Engineered recombinant human paraoxonase 1 (rHuPON1) purified from Escherichia coli protects against organophosphate poisoning. Proc Natl Acad Sci U S A (2008) 1.24
Paraoxonase 1 (PON1) status and substrate hydrolysis. Toxicol Appl Pharmacol (2008) 1.21
CLIA-tested genetic variants on commercial SNP arrays: potential for incidental findings in genome-wide association studies. Genet Med (2010) 1.21
Paraoxonase gene mutations in amyotrophic lateral sclerosis. Ann Neurol (2010) 1.20
Predictors of impaired neurodevelopmental outcomes at one year of age after infant cardiac surgery. Eur J Cardiothorac Surg (2009) 1.17
Return of incidental findings in genomic medicine: measuring what patients value--development of an instrument to measure preferences for information from next-generation testing (IMPRINT). Genet Med (2013) 1.16
Return of results: ethical and legal distinctions between research and clinical care. Am J Med Genet C Semin Med Genet (2014) 1.16
Serum cholinesterase inhibition in relation to paraoxonase-1 (PON1) status among organophosphate-exposed agricultural pesticide handlers. Environ Health Perspect (2009) 1.14
Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on. Biochem Pharmacol (2010) 1.14
Novel paraoxonase (PON1) nonsense and missense mutations predicted by functional genomic assay of PON1 status. Pharmacogenetics (2003) 1.14
Multiple genome-wide analyses of smoking behavior in the Framingham Heart Study. BMC Genet (2003) 1.14
Genomic scan of 254 hereditary prostate cancer families. Prostate (2003) 1.14
High density GWAS for LDL cholesterol in African Americans using electronic medical records reveals a strong protective variant in APOE. Clin Transl Sci (2012) 1.13
Heritability of longitudinal measures of body mass index and lipid and lipoprotein levels in aging twins. Twin Res Hum Genet (2007) 1.12
Surface plasmon resonance detection using antibody-linked magnetic nanoparticles for analyte capture, purification, concentration, and signal amplification. Anal Chem (2009) 1.11
Genetic factors are important determinants of neurodevelopmental outcome after repair of tetralogy of Fallot. J Thorac Cardiovasc Surg (2008) 1.10
Identifying patients at high risk of a cardiovascular event in the near future: current status and future directions: report of a national heart, lung, and blood institute working group. Circulation (2010) 1.07
Detection of Staphylococcus aureus enterotoxin B at femtomolar levels with a miniature integrated two-channel surface plasmon resonance (SPR) sensor. Biosens Bioelectron (2002) 1.06
Exome sequencing reveals novel rare variants in the ryanodine receptor and calcium channel genes in malignant hyperthermia families. Anesthesiology (2013) 1.06
Paraoxonase 1 (PON1) modulates the toxicity of mixed organophosphorus compounds. Toxicol Appl Pharmacol (2009) 1.06
The correlation of paraoxonase (PON1) activity with lipid and lipoprotein levels differs with vascular disease status. J Lipid Res (2005) 1.06
Genetic variation associated with circulating monocyte count in the eMERGE Network. Hum Mol Genet (2013) 1.05
Genetic Loci implicated in erythroid differentiation and cell cycle regulation are associated with red blood cell traits. Mayo Clin Proc (2012) 1.05
Development of diagnostics in the search for an explanation of aerotoxic syndrome. Anal Biochem (2010) 1.04
Analysis of recently identified dyslipidemia alleles reveals two loci that contribute to risk for carotid artery disease. Lipids Health Dis (2009) 1.03
Exposure to tri-o-cresyl phosphate detected in jet airplane passengers. Toxicol Appl Pharmacol (2011) 1.03
Role of paraoxonase (PON1) status in pesticide sensitivity: genetic and temporal determinants. Neurotoxicology (2005) 1.02
Portable 24-analyte surface plasmon resonance instruments for rapid, versatile biodetection. Biosens Bioelectron (2007) 1.02
Characterizing genetic variants for clinical action. Am J Med Genet C Semin Med Genet (2014) 1.02
Repeated developmental exposure of mice to chlorpyrifos oxon is associated with paraoxonase 1 (PON1)-modulated effects on cerebellar gene expression. Toxicol Sci (2011) 1.02
A portable surface plasmon resonance sensor system for real-time monitoring of small to large analytes. J Ind Microbiol Biotechnol (2005) 1.01
Refining the structure and content of clinical genomic reports. Am J Med Genet C Semin Med Genet (2014) 1.00